To see or not to see: In vivo nanocarrier detection methods in the brain and their challenges
Journal of Controlled Release · 2024-07 · 371 · 216-236
DOI: 10.1016/j.jconrel.2024.05.044 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2024-07. Verfasst von Antonia Clarissa Wehn und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Stroke and Dementia Research (ISD), Munich University Hospital, Feodor-Lynen-Straße 17, 81377, Germany; Department of Neurosurgery, Uni…. Hauptthemen laut MEDLINE: Nanoparticles, Brain, Blood-Brain Barrier, Drug Carriers. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 418 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Nanoparticles have a great potential to significantly improve the delivery of therapeutics to the brain and may also be equipped with properties to investigate brain function. The brain, being a highly complex organ shielded by selective barriers, requires its own specialized detection system. However, a significant hurdle to achieve these goals is still the identification of individual nanoparticles within the brain with sufficient cellular, subcellular, and temporal resolution. This review aims to provide a comprehensive summary of the current knowledge on detection systems for tracking nanoparticles across the blood-brain barrier and within the brain. We discuss commonly employed in vivo and ex vivo nanoparticle identification and quantification methods, as well as various imaging modalities able to detect nanoparticles in the brain. Advantages and weaknesses of these modalities as well as the biological factors that must be considered when interpreting results obtained through nanotechnologies are summarized. Finally, we critically evaluate the prevailing limitations of existing technologies and explore potential solutions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Stroke and Dementia Research (ISD), Munich University Hospital, Feodor-Lynen-Straße 17, 81377, Germany; Department of Neurosurgery, University of Munich Medical Center, Marchioninistraße 17, 81377 Munich,…
- Institute for Stroke and Dementia Research (ISD), Munich University Hospital, Feodor-Lynen-Straße 17, 81377, Germany. Electronic address: eva.krestel@med.uni-muenchen.de.
- Laboratoire de Biophotonique et Pharmacologie, CNRS UMR 7213, Université de Strasbourg, 74 route du Rhin - CS 60024, 67401 Illkirch Cedex, France. Electronic address: andrey.klymchenko@unistra.fr.
- Institute for Stroke and Dementia Research (ISD), Munich University Hospital, Feodor-Lynen-Straße 17, 81377, Germany; Munich Cluster of Systems Neurology (SyNergy), Feodor-Lynen-Straße 17, 81377 Munich, Germany. Electro…
- Institute for Stroke and Dementia Research (ISD), Munich University Hospital, Feodor-Lynen-Straße 17, 81377, Germany; Normandie University, UNICAEN, INSERM UMR-S U1237, Physiopathology and Imaging of Neurological Disord…
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Wehn, A. C., Krestel, E., Harapan, B. N., Klymchenko, A., Plesnila, N., & Khalin, I. (2024). To see or not to see: In vivo nanocarrier detection methods in the brain and their challenges. Journal of Controlled Release, 371, 216-236. https://doi.org/10.1016/j.jconrel.2024.05.044
Vancouver
Wehn AC, Krestel E, Harapan BN, Klymchenko A, Plesnila N, Khalin I. To see or not to see: In vivo nanocarrier detection methods in the brain and their challenges. Journal of Controlled Release. 2024;371:216-236. doi:10.1016/j.jconrel.2024.05.044
BibTeX
@article{Wehn2024,
author = {Wehn, Antonia Clarissa and Krestel, Eva and Harapan, Biyan Nathanael and Klymchenko, Andrey and Plesnila, Nikolaus and Khalin, Igor},
title = {To see or not to see: In vivo nanocarrier detection methods in the brain and their challenges},
journal = {Journal of Controlled Release},
year = {2024},
volume = {371},
pages = {216--236},
doi = {10.1016/j.jconrel.2024.05.044}
}
EUVIMED